



8th EUROD Winter Meeting

Programme

January 15-17, 2025

Venue: Convent of Chièvres,
Leuven, Belgium

EUROD
European Renal Osteodystrophy

CKD-MBD
Chronic Kidney Disease Mineral
and Bone Disorder

Wednesday, January 15, 2025

13:00 – 13:10 Welcome (Pieter Evenepoel, Katholieke Universiteit and University Hospitals Leuven, Leuven, Belgium)

13:15 – 14:45: Young Investigator Workshop: The utility of DXA imaging in CKD

Get to know clinical bone imaging in-depth, by rotating through three hands-on sessions of 25 minutes each, with ample time for interaction with the experts.

Chair: Maria Jesus Lloret (Hospital Fundació Puigvert, Barcelona, Spain)

- 13:15 - 13:40 Session A (room: Willem Van Croy): **Opportunities and pitfalls of DXA in CKD (Marie-Helene Lafage-Proust, University of Lyon, St. Etienne, France)**
- 13:45 - 14:10 Session B (room: St. Barbara): **Importance of vertebral fracture assessment in CKD (Maria Fusaro, University of Padova, Padova, Italy & Syazrah Salam, Sheffield Teaching Hospitals, Sheffield, United Kingdom)**
- 14:15 - 14:40 Session C (room: Anna De Paepe): **Novel opportunities with DXA scans; 3D DXA, hip strength analysis, TBS (Andrea Trombetti, University of Geneva, Geneva, Switzerland)**

14:45 – 15:30 Coffee break and Poster Session 1

15:30 – 17:30 Clinical Hot Topics

Chair: Hanne Skou Jørgensen (Aalborg University, Aalborg, Denmark) & Maria Fusaro (University of Padova, Padova, Italy)

- 15:30 - 15:55 **Update from the 2024 KDIGO Controversies Conference on CKD-MBD: Paradigm shifts and future directions (Markus Ketteler, Robert-Bosch Hospital, Stuttgart, Germany)**
- 16:00 - 16:25 **Nutritional vitamin D in CKD – report from a European consensus (Marc Vervloet, Radboud University Medical Center, Nijmegen, The Netherlands)**
- 16:30 - 16:55 **Metabolic acidosis: An appealing therapeutic bone target in CKD and beyond? (Nilufar Mohebbi, University of Zurich, Zurich, Switzerland)**
- 17:00 - 17:25 **Lessons from the osteoporosis world; recent trials of relevance in CKD (Michaël Laurent, Imelda Hospital, Bonheiden, Belgium)**

18:30 Meet & Greet in Leuven (Radiohuis, registration required)

Thursday, January 16, 2025

11:00 – 12:30: Mineral metabolism and bone in rare renal diseases

Gain mechanistic insights into mineral and bone disorders by considering how rare renal disease may impact the CKD-MBD syndrome.

Chairs: Justine Bacchetta (University of Lyon, Lyon, France) & Djalila Mekahli (Katholieke Universiteit and University Hospitals Leuven, Leuven, Belgium)

- 11:05 - 11:25 **Bone metabolism in ADPKD (Magdalena Jankovska**, Medical University of Gdańsk, Gdańsk, Poland)
- 11:30 - 11:55 **The role of RNAi on bone disease in primary hyperoxaluria type 1 (Justine Bacchetta**, University of Lyon, Lyon, France)
- 12:00 - 12:25 **Differential diagnoses of hypophosphatemia (Julien Paccou**, Hospital Salengro, Lille, France)

12:30 – 13:30 Lunch

13:30 – 18:00 Research Forum

The EUROD research forum gathers basic and clinical researchers, focusing on scientific progress in renal bone disease. The mission of the EUROD Research Forum is to share knowledge, foster collaboration, and enhance networking. The EUROD research forum comprises a mixture of invited mini-lectures, selected free communications, and short pitches, with ample time for discussion.

13:30 – 15:00 Research Forum part 1

Chairs: Marie-Hélène Lafage-Proust (University of Lyon, St. Etienne, France) & Juan Miguel Diaz Tocados (Biomedical Research Institute of Lleida, Lleida, Spain)

- 13:30 - 13:45 (FC): **Myocardial remodeling in mild CKD-MBD is associated with PIT1/2 dysregulation and systemic phosphate redistribution (Evdokia Bogdanova**, Pavlov University, Saint Petersburg, Russia)
- 13:50 - 14:05 (FC): **SEAPORT 1: An Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of INZ-701 (ENPP1-Fc) in Participants with End-Stage Kidney Disease Undergoing Hemodialysis (Yves Sabbagh**, Inozyme Pharma, Boston, Massachusetts, US)
- 14:10 - 14:30 (ML): **The effect of incretins on skeletal health (Jakob Starup-Linde**, Aarhus University, Aarhus, Denmark)
- 14:35 - 14:55 (ML): **Advanced glycation end-products and bone metabolism (Nicola Napoli**, Campus Bio-Medico University Hospital Foundation, Rome Italy)

15:00 – 16:00 Coffee break and Posters

16:00 – 17:45 Research Forum part 2

Chairs: Nathalie Bravenboer (University Medical Center Amsterdam, Amsterdam, The Netherlands) & Anja Verhulst (University of Antwerp, Antwerp, Belgium)

- 16:00 - 16:20 (ML) **Metabolic regulation of skeletal cell fate and function (Steve Stegen**, Katholieke Universiteit and University Hospitals Leuven, Leuven, Belgium)

- 16:25 - 16:40 (FC): **Bone Sialoprotein Regulates Phosphate Metabolism and reduces CKD-MBD in Mice** (**Marie-Hélène Lafage-Proust**, University of Lyon, St. Etienne, France)
- 16:45 - 17:00 (FC): **Effect of CKD-MBD Phenotypes on CKD Progression and Mortality in Diabetic and Non-Diabetic Elderly Patients with Advanced CKD – Results from the EQUAL Study** (**Lorenza Magagnoli**, University of Milan, Milan, Italy)
- 17:05 - 17:25 (ML): **Interaction between glucose and phosphorus metabolism** (**Martin de Borst**, University Medical Center Groningen, Groningen, the Netherlands)
- 17:30 - 17:50 (P): **Calcify2D – a novel technique for simultaneous assessment of vertebral fractures and vascular calcification** (**Maria Fusaro**, University of Padova, Padova, Italy)

17:50 – 18:00 Best Abstract Awards (**Pieter Evenepoel**, Katholieke Universiteit, and University Hospitals Leuven, Leuven, Belgium)

19:00 Network Dinner
(**De Optimist**, registration required)

Friday, January 17, 2025

08:30 – 16:00: Diabetes and CKD-MBD: partners in crime

Diabetes mellitus (DM) is not only the most common cause of CKD, but also a prevalent comorbidity in patients with CKD. DM significantly inflates the risk of vascular calcification and fractures in patients with CKD. Although underlying pathophysiological mechanisms remain largely obscure, current evidence points to insulin resistance, advanced glycation end products and cellular senescence as important culprits. A better understanding of these mechanisms may unveil promising therapeutic targets. Meanwhile, the landscape of diabetes treatment in patients with advanced CKD is rapidly evolving. Next to glycemic control, cardiovascular and skeletal protection are important considerations when making treatment choices.

08:30 – 08:45 Welcome (Pieter Evenepoel, UZ/KU Leuven, Belgium)

Chairs: Christa Maes (Katholieke Universiteit, Leuven, Belgium) & Mathias Haarhaus (Karolinska Institute, Stockholm, Sweden)

08:45 – 10:00: Pathophysiological mechanisms at the crossroad of diabetes and CKD

- 08:45 - 09:15 **Insulin resistance: innocent bystander or mediator of vascular and skeletal disease? (Thomas Ebert, University Hospital Leipzig, Leipzig, Germany)**
- 09:20 - 09:50 **Advanced glycation end-products: innocent bystanders or mediators of vascular and skeletal disease? (Casper Schalkwijk, University Medical Center Maastricht, Maastricht, the Netherlands)**

10:00 – 10:40 Coffee break

10:40 – 12:00 Impact of diabetes on bone and vascular health

Chairs: Anibal Ferreira (Hospital Curry Cabral, Lisbon, Portugal) & Hanne Skou Jørgensen (Aalborg University and Aalborg University Hospital, Aalborg, Denmark)

- 10:40 - 11:10 **Diabetes and bone health in patients with and without CKD (Serge Ferrari, University of Geneva, Geneva, Switzerland)**
- 11:20 - 11:50 **Crosstalk between bone and vasculature in diabetes and CKD (Maria Mace, University of Copenhagen, Copenhagen, Denmark)**

12:00 – 13:00 Lunch

13:00 – 15:00 Targeting diabetes and fracture risk in patients with CKD

Chairs: Pieter Evenepoel (Katholieke Universiteit, Leuven, Belgium) & Syazrah Salam (Sheffield Teaching Hospital, Sheffield, UK)

- 13:00 - 13:35 **Diabetes therapy standards in patients with CKD (Pieter Gillard, University Hospitals Leuven, Leuven, Belgium)**
- 13:45 - 14:05 **Effect of antidiabetic treatment on bone (Cristiana Cipriani, Sapienza University of Rome, Rome, Italy)**
- 14:15 - 14:50 **How do we address fracture risk in diabetic patients? (Richard Eastell, University of Sheffield, Sheffield, United Kingdom)**

15:00 Concluding remarks (Pieter Evenepoel, Katholieke Universiteit and University Hospitals Leuven, Leuven, Belgium)

15:15 – 16:00 Coffee and Networking

Posters session 1

1. Association between Bone Mineral Density and C-Reactive Protein in Patients with Kidney Failure (**Dieter Smout**, Belgium)
2. Fracture risk in pre-dialysis chronic kidney disease (**Hanne Skou Jørgensen**, Denmark)
3. Online fracture risk prediction tools in patients with ADPKD: Practical Use and Barriers to Implementation (**Magdalena Jankowska**, Poland)
4. Impact of Autosomal Dominant Polycystic Kidney Disease on fracture risk following kidney transplant (**Jabber Laoui**, Belgium)
5. Post-transplant hyperparathyroidism as a risk factor for diabetes and graft failure (**Ahmet Murt**, Türkiye)
6. Metformin and FGF23 in diabetic CKD patients: exploring potential associations (**Lydia Ziouani**, France)
7. Bone turnover markers behaviour during the first year post-kidney transplantation (**Susa Lloret**, Spain)
8. Diabetes mellitus, mineral-bone disorders and microRNAs in dialysis patients – is there a connection? (**Anastasiia Rind**, Russia)
9. Radiofrequency Echographic Multi Spectrometry (REMS) for bone health assessment in patients on chronic hemodialysis (**Lisa Stefani**, Italy)
10. Time to get calciphylaxis on clinicians' RaDaR? - A multicentre case series (**Sharon Huish**, United Kingdom)
11. CKD-MBD management: results from a national survey on bone turnover biomarkers practice and therapeutic strategies among Italian nephrologists (**Althea Cossettini**, Italy)
12. Long-Term changes in parameters of bone quality in kidney transplant recipients treated with Denosumab (**Lisa Stefani**, Italy)
13. Unravelling the microvasculature of human cortical bone: a concept for a comparative study between microcomputed tomography and histopathology (**Steven Van Offel**, Belgium)
14. Efficacy and safety of SGLT2i in the elderly with CKD (**Godanci Kelmendi**, Kosovo)

Posters session 2

15. Bone Turnover and Bone Density in Chronic Kidney Disease: a Translational Study (**Dieter Smout**, Belgium)
16. Diagnostic agreement of bone histomorphometry for a diagnosis of renal osteodystrophy (**Hanne Skou Jørgensen**, Denmark)
17. Effect of antiresorptive treatment on bone strength measured in vivo by impact microindentation 1 year post-kidney transplantation (**Susa Lloret**, Spain)
18. Bone quality in chronic kidney disease patients with and without diabetes mellitus (**Syazrah Salam**, United Kingdom)
19. Temporal trends in the risk of fractures during 2000-2022 in adult kidney transplant recipients (**Ina Karstoft Ystrøm**, Denmark)
20. High glucose exacerbates high-phosphate induced endothelial calcification (**Paola Ciceri**, Italy)
21. Vitamin K dependent proteins and bone quality in the first year after kidney transplantation (**Althea Cossettini**, Italy)
22. Association between Bone Mineral Density and Sarcopenia Parameters in patients with Chronic Kidney Disease stages 4-5: a cross-sectional study (**Anahita Rashid**, Denmark)
23. The impact of Renal Osteodystrophy subtypes on fractures in predialysis CKD patients (**Mariana Diz Lopes**, Portugal)
24. Familial Renal Glycosuria: a model for unveiling the impact of SGLT2 inhibition on bone health and mineral metabolism (**Merita Rroji**, Albania)
25. Avascular necrosis and risk factors in kidney transplant recipients: a single-center experience (**Omer Faruk Akay**, Türkiye)
26. Association of parathyroid hormone and alkaline phosphatase with fracture risk in patients with chronic kidney disease not on dialysis (**Caroline Sophie Hjelm Pichat**, Denmark)
27. Exploring the impact of intravenous iron on CKD-induced bone pathology (**Astrid Van den Branden**, Belgium)
28. CKD-associated osteoporosis in an academic dialysis unit: a wake-up call (**Thijs Engelen**, Belgium)

Supported by unrestricted financial support by

Diamond

CSL Vifor

Silver

AMGEN

AstraZeneca

KYOWA KIRIN



Inspired by patients.
Driven by science.



novo nordisk®

Bronze

Alnylam®
PHARMACEUTICALS

ascendis
pharma



Boehringer
Ingelheim



inozyme
pharma

With the support of

fwo Opening new horizons



EUROD

Winter Meeting

Leuven, Belgium

Bones at the heart of CKD

